Theralase Identifies the First Cancer Target for its Advanced Photo Dynamic Therapy

Theralase to Focus Research on Bladder Cancer in Clinical Trials

Toronto, Ontario – July 18, 2012, Theralase Technologies Inc. (TSX-V: TLT) announced today that it has selected bladder cancer as the first clinical target in its Novel Photo Dynamic Compound (PDC) research. Theralase now has a clear direction with which to proceed with FDA Clinical Trials.

Bladder cancer is the fifth most common cancer in North America being the fourth most common in men and the eighth most common in woman. In North America, it is estimated that there will be over 77,000 new cases and over 15,000 deaths annually. "With a recurrence rate of nearly 80%, bladder cancer is the most expensive cancer to treat on a per patient basis," says Dr. Michael Jewett, a specialist in uro-oncology and member of Bladder Cancer Canada's Medical Advisory Board. "The high recurrence rate raises many issues affecting quality of life."

Dr Arkady Mandel, Chief Scientific Officer of Theralase said, “We have successfully continued development of the innovative anticancer platform technology that will be first tested in the models of bladder cancer in our labs.  Besides the strong scientific and clinical rationale for successful therapeutic application of Theralase’s advanced phototherapy in this patient population”, continued Dr. Mandel, “there have been no significant advances in bladder cancer treatment in several decades.  We are hopeful that the highly promising results of our research will move the field forward. Bladder cancer is a significant health concern. It is estimated that $2.9 billion is spent in the United States alone each year on the treatment of bladder cancer. We feel our technology will prove as effective in bladder cancer preclinical trials that will eventually lead to FDA clinical approval.”

July has been designated as “Bladder Cancer Awareness Month” in North America and we pray that our announcement is both timely and provides hope for the patients stricken with this devastating disease,” said Roger Dumoulin-White, President and CEO of Theralase. He added, “The Theralase light activated PDC drug has been proven to be superior to any currently approved FDA PDC drug on the market, tested in our lab and we are working hard to help eliminate this devastating disease that can dramatically affect so many families. Theralase plans to aggressively pursue commercialization of our ground-breaking PDC technology through the accelerated FDA regulatory approval process.  This FDA process is able to "fast-track" approval when a treatment is shown, through proven success rate, to have a positive impact on a serious, life-threatening medical conditions for which no other drug or treatment exists or is as effective.”

About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high quality products. Theralase also develops patented Photo Dynamic Compound (PDC) technology focused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com  , regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Cold Laser For Smoking Cessation

Cold Laser for Smoking Cessation Date: Thursday, July 19th, 2012 Time: 1:00 PM - 2:00 PM EDT   Below are a few items that will be covered in the Webinar:  1.      How does cold laser help smokers quit?  2.      What is the correct laser treatment protocol?  3.      What type of laser system works best for smoking cessation treatments?  4.      How does the efficacy of laser compare to other quit smoking techniques? 5.      What is required in setting up a stop smoking program? TO REGISTER https://www2.gotomeeting.com/register/638356450 After registering you will receive a confirmation email containing information about joining the Webinar. System Requirements PC-based attendees Required: Windows® 7, Vista, XP or 2003 Server Macintosh®-based attendees Required: Mac OS® X 10.5 or newer Regards, The Theralase Team Links www.theralase.com Theralase Laser Clinic Clinic Locator

Laser Therapy in Rehabilitation

By Perry Nickelston, DC, FMS, SFMA

Effective rehabilitation protocols require a strategic and comprehensive approach integrating soft-tissue techniques, fascial manipulation, joint manipulation, and functional movement patterning.

Restoring optimal range of motion and reducing pain by transitioning the patient from passive to active care should be the primary goal. Decreasing the time they spend in the passive phase of care and teaching painless, functional, active rehab of the kinetic chain will help improve compliance.

Using therapeutic modalities to significantly increase recovery times and heal chemically damaged cells while strengthening surrounding tissue can decrease passive therapy and accelerate the natural regeneration process of injured areas. Laser therapy can be the modality you have been searching for to enhance clinical outcomes and patient satisfaction. Understanding the therapeutic mechanisms of action involved with laser therapy and treatment protocols is essential. Successful use of any modality in clinical practice ultimately depends on the expertise and skill of the practitioner. Let's take an in-depth look at the physiological benefits of laser therapy and how it can be integrated into rehabilitation programs.

The U.S. Food and Drug Administration (FDA) approved the first low-level class III laser (LLLT) in 2002 and the first class IV therapy laser in 2003. The most significant clinical and therapeutic difference between class III and class IV lasers is the class IV laser's higher power output may produce a primary biostimulative effect on deeper tissues. Reaching deep-tissue structures is critical to rehabilitation and recovery. If you cannot reach the intended target tissue with adequate therapeutic laser dosages, your overall clinical results will diminish.
LLLT excites the kinetic energy within cells by transmitting healing energy known as photons. The skin absorbs these photons via a photochemical effect, not a photothermal one; therefore, it does not cause heat damage to tissues. As such, laser can be safely used on patients who have metal joint replacements without the risk of injury.
Laser light does not excite or interact with the molecules in metal or plastic. Once photons reach the cells of the body, they promote a cascade of cellular activities, including igniting the production of enzymes, stimulating mitochondria, increasing vasodilation and lymphatic drainage, ATP synthesis, and elevating collagen formation substances to prevent the formation of scar tissues. This is a critical step in reducing long-term, disabling myofascial pain syndromes and joint restrictions.
Photobiomodulation, otherwise known as laser biostimulation, is the medical term for exposure to laser light that enhances tissue growth and healing. Here is a partial list of the positive effects of photobiomodulation in the body, all of which are crucial components of long-term healing:

• Increased leukocyte activity (acceleration of tissue repair and decrease of pain)
• Increased neovascularization (new vessel growth and increased oxygenation)
• Increased fibroblast production (speeds tissue repair)
• Increased tensile strength (helps prevent reinjury)
• Stabilization of cellular membrane of damaged cells
• Enhancement of ATP production and synthesis
• Decreased C-reactive protein and neopterin; acceleration of leukocytic activity
• Enhanced lymphocyte response with reduction of interleukin 1 (IL-1)
• Increased prostaglandin synthesis
• Enhanced superoxide dismutase (SOD) levels
• Stimulation of vasodilation with increased angiogenesis (new blood vessels)

Principle factors of success with laser therapy for fascial restrictions and joint rehabilitation include optimal dosage, power, wavelength, and accurate clinical diagnoses.
Maintaining or restoring movement of specific segments is the key to preventing or correcting musculoskeletal pain. Fundamentally, rehabilitation is about movement – and lots of it. The foundation of functional movement is proper joint mobility and stability. Without adequate mobility and stability of joints in the kinetic chain, you end up with dysfunctional movement.
Activities of daily living are then built on dysfunctional movement patterns, resulting in compensation and injury. Microtrauma results from small amounts of stress imposed on the body over time caused by poor biomechanics; the body compensates with suboptimal joint alignment, muscle coordination, and posture. Joints begin approximating in an effort to gain stability lost from muscular weakness and compensation. This process, known as "joint centration," is an inherent protective mechanism of the body. If left uncorrected, it may cause osteoarthritis, degeneration and decreased mobility.
As I've said previously, the central nervous system (CNS) learns postural movement patterns early in life. Overactivation of abnormal joint reflexes may alter spinal cord memory, and the brain comes to rely on this faulty information. Neurogenic muscle activation patterning by combining laser therapy and functional movement rehabilitation can help "reprogram" the CNS to improve function and reverse abnormal patterning.
Laser affects areas prior to active movement patterning to accelerate the metabolic rate of deep-tissue structures. Laser therapy on muscle attachment sites can increase a cascade of neurological input to the CNS enhancing proprioceptive awareness. In my experience, most rehabilitation cases require 6-10 laser therapy sessions for maximum benefit, depending on the individual and class of laser used for treatment. Laser affects joints and surrounding tissue with a therapeutic dose following current research of (4-12 J/cm2) depending on depth of tissue. (Joules is the measurement of photon energy, represented in J/cm2.)
Each therapy program is different depending on the unique circumstances of each movement pattern dysfunction. There is no baseline laser therapy program for pain syndromes. The history of each patient determines the laser therapy protocols you implement. The above dosage range is a benchmark foundation for treatment. Reassess after the fourth laser therapy session to document progress and the possible need for change in therapy protocols.
Resources

• Cook G. Movement: Functional Movement Systems : Screening, Assessment, and Corrective Strategies. Santa Cruz, CA: On Target Publications, 2010.
• Tuner J, Hode L. The Laser Therapy Handbook. Grangesberg, Sweden: Prima Books, 2004.
• Turchin C. Light and Laser Therapy: Clinical Procedures, Second Edition. 2006.
• Boyle M. Functional Training for Sports. Champaign, IL: Human Kinetics, 2004.
• Cook G, Kiesel K, Plisky P. The Selective Functional Movement Assessment: An Integrated Model to Address Regional Interdependence. Presented at the 2009 American Academy of Orthopedic Manual Physical Therapists conference.
• Riegel R, Pryor B. Clinical Overview and Applications of Class IV Therapy Lasers. 2008
• Sahrmann S. Diagnosis and Treatment of Movement Impairment Syndromes. St. Louis: Mosby, 2002.

For more information Please call 1-866-843-5273 or visit www.theralase.com 

---